Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) traded down 7.5% on Wednesday . The stock traded as low as $15.74 and last traded at $15.85, with a volume of 132,076 shares trading hands. The stock had previously closed at $17.13.

Several equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 20th. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $24.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $25.00.

The stock has a 50-day moving average price of $12.82 and a 200-day moving average price of $13.16. The company’s market capitalization is $243.44 million.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. Equities analysts expect that Syndax Pharmaceuticals Inc. will post ($3.01) EPS for the current year.

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.